Mastering EGFR Testing and Targeted Therapy in Advanced NSCLC: From Molecular Profiling to Multidisciplinary Mastery

10 episodes
1.00 program credits
1h 06m
MinuteCE®
ReachMD Healthcare Image
Details
Episodes
Presenters
  • Overview

    This program is intended for ex-US HCPs only including medical oncologists, pulmonologists and pathologists. If you do not qualify as such please close the program. If you do qualify please begin this course.

    This online CME activity focuses on multidisciplinary team collaboration in the treatment and management of EGFR-mutated advanced NSCLC. Participants will hear from a multidisciplinary expert panel to learn how to integrate the latest clinical evidence and guideline recommendations into personalized treatment plans for patients with EGFR-mutated advanced NSCLC. The international expert panel will also offer insights on optimal molecular testing; treatment administration, selection, and sequencing; managing adverse events; and strengthening multidisciplinary collaboration. 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Byoung Chul Cho, MD, PhD
    Professor, Yonsei Cancer Center
    Yonsei University College of Medicine
    Seoul, Republic of Korea

    Dr. Cho has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 

    Advisor/Consultant: Amgen, AnHeart Therapeutics, ArriVent, AstraZeneca, BeiGene, BMS, Boehringer-Ingelheim, BridgeBio Therapeutics, CJ Bioscience, Cyrus Therapeutics, Daiichi Sankyo, Eli Lilly, Gilead, GSK, Guardant Health, Harpoon Therapeutics, J INTS BIO, Janssen, KANAPH Therapeutic Inc, MSD, Novartis, Ono, Pfizer, Regeneron, Roche, Sanofi, Seagen, Takeda, Therapex, Yuhan
    Contracted Researcher: AstraZeneca, Champions Oncology, CJ Bioscience, Cyrus Therapeutics, Dong-A ST, GI Innovation, ImmuneOncia, Janssen, J INTS BIO, MSD, Therapex, Vertical Bio AG, Yuhan
    Royalties: Champions Oncology, Crown Bioscience, Imagen, PearlRiver Bio GmbH
    Speaker’s Bureau: ASCO, AstraZeneca, The Chinese Thoracic Oncology Society, ESMO, Guardant Health, IASLC, Korean Cancer Association, Korean Cancer Study Group, Korean Society of Medical Oncology, Korean Society of Thyroid-Head and Neck Surgery, MSD, Novartis, Pfizer, Roche, Zailab
    Stock/Share Ownership: BridgeBio Therapeutics, Cyrus Therapeutics, Gencurix Inc,  Interpark Bio Convergence Corp, J INTS BIO, KANAPH Therapeutic Inc, TheraCanVac Inc

    Keith M. Kerr, MB ChB, FRCPath
    Consultant Pathologist/Professor
    Aberdeen University MS & Royal Infirmary
    Aberdeen, Scotland

    Dr. Kerr has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 

    Advisor/Consultant: AbbVie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Medscape, Merck Serono, Merck Sharp & Dohme, Mirati, Novartis, PeerVoice, PER, Pfizer, Prime Oncology, Roche, Sanofi, Takeda, Ventana

    Natasha B. Leighl, MD, MMSc
    Professor, Department of Medicine
    Adjunct Professor, Institute of Health Policy
    University of Toronto
    Ontario, Canada

    Dr. Leighl has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 

    Contracted Researcher: AstraZeneca Canada, Inivata/NeoGenomics, Janssen Oncology, Lilly, MSD, Novartis, Pfizer

    Reviewers/Content Planners/Authors: 

    • Cindy Davidson has no relevant relationships to disclose.
    • Jocelyn Timko has no relevant relationships to disclose.
    • Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose. 
  • Learning Objectives

    Upon completion of this activity, learners should be better able to: 

    • Apply comprehensive molecular-profiling strategies to identify clinically actionable genomic alterations that inform treatment selection and sequencing in advanced/metastatic non–small cell lung cancer (NSCLC)
    • Incorporate evidence- and guideline-recommended approaches to develop personalized treatment plans for patients with epidermal growth factor receptor–mutated (EGFRm) advanced/metastatic NSCLC
    • Implement effective multidisciplinary team strategies to optimize treatment administration, monitoring, and adverse event management for EGFRm-directed therapies
  • Target Audience

    This activity has been designed to meet the educational needs of ex-US oncologists and pulmonologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with NSCLC.  

  • Accreditation and Credit Designation Statements

    EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.

    Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

    EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).

    This enduring activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC®) for 50 minutes of effective education time.  

  • Provider(s)/Educational Partner(s)

        
    Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice. 


    Medcon International partners with the ECO Foundation a non-profit medical professional organization in Spain founded by oncology and hematology department heads of the leading cancer centers in the country and has a great network across Europe.

     

  • Commercial Support

    This activity is supported by an independent educational grant from Johnson & Johnson. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medcon International and ECO. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medcon International and ECO you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited 

    Reproduction of this materialis not permitted without written permission from the copyright owner.  

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

NEW FEATURES:

Register

We're glad to see you're enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free